Memantine is not an antipsychotic. It belongs to an entirely different drug class: it is an NMDA receptor antagonist, approved by the FDA to treat moderate-to-severe Alzheimer’s disease. The confusion is understandable, though, because memantine has shown up in psychiatric research for conditions like schizophrenia, autism, and bipolar disorder, and it can reduce some behavioral symptoms that overlap with what antipsychotics target. The story of how a dementia drug ended up in psychiatric conversations is more interesting than a simple classification label suggests.
How Memantine Actually Works
Antipsychotics work primarily by blocking dopamine receptors, particularly a subtype called D2. That is the pharmacological backbone of every conventional and most atypical antipsychotic on the market. Memantine does something fundamentally different. It blocks NMDA receptors, which are gated channels involved in glutamate signaling, the brain’s main excitatory neurotransmitter system. Specifically, memantine is an “open channel blocker,” meaning it can only enter and block the receptor’s ion channel after that channel has already been activated by glutamate.1Current Opinion in Pharmacology. Mechanism of action of memantine
What makes memantine unusual among NMDA blockers is its moderate affinity and fast kinetics. It does not slam the receptor shut and hold it closed the way a high-affinity blocker would. Instead, it steps in during periods of excessive, low-level glutamate “noise” and gets out of the way when a strong, meaningful signal comes through. This selective filtering is thought to explain how it can be neuroprotective without wiping out normal learning and memory. The drug essentially dials down background static while preserving the signal.2PubMed. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system–too little activation is bad, too much is even worse
This is worth emphasizing because another well-known NMDA blocker, ketamine, acts on the same receptor type with similar affinity yet produces dramatically different behavioral effects, including psychosis-like symptoms at higher doses. The two drugs diverge at higher concentrations, likely because of differences in how they interact with the receptor or because of secondary targets.3PubMed Central. Comparison of behavioral effects of the NMDA receptor channel blockers memantine and ketamine in rats Memantine, at its clinical doses, does not produce the dissociative or psychotomimetic effects associated with ketamine. That safety profile is a large part of why researchers have been comfortable testing it in psychiatric populations.
What Memantine Is FDA-Approved For
In 2003, memantine became the first drug approved by the FDA for moderate-to-severe Alzheimer’s disease.4PubMed. Use of memantine for the treatment of dementia It remains in that lane today. Its approval was based on evidence that it modestly improves cognition and daily functioning in people with more advanced Alzheimer’s, and it is frequently prescribed alongside a cholinesterase inhibitor like donepezil. The improvements are not dramatic, and memantine does not reverse or halt the disease, but it can slow the decline in some patients enough that families and clinicians find the benefit meaningful.
Every other psychiatric or neurological use of memantine is off-label, meaning the drug is being prescribed for a condition the FDA has not formally approved it to treat. Off-label use is common in psychiatry and is not inherently problematic, but it does mean the evidence base is typically smaller and less settled than it is for an approved indication.
Why Memantine Keeps Showing Up in Psychosis Research
The glutamate hypothesis of schizophrenia is one reason memantine has attracted psychiatric interest. For decades, the dominant theory of schizophrenia focused on dopamine, but a parallel line of research has implicated NMDA receptor dysfunction. If NMDA receptors are not working properly, the downstream signaling cascades go awry, and some researchers believe this contributes to the “negative” symptoms of schizophrenia: social withdrawal, flattened emotion, reduced motivation, poverty of speech. These symptoms are notoriously resistant to conventional antipsychotics, which do a much better job controlling “positive” symptoms like hallucinations and delusions.
That gap is exactly where memantine has been tested. A meta-analysis pooling seven trials found that adding memantine to existing antipsychotic treatment improved negative symptoms, with a large effect size. It also improved scores on the Mini-Mental Status Examination, a rough measure of cognitive function.5PubMed. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis A separate systematic review reached a similar conclusion: memantine seemed to help with negative symptoms while positive symptoms and general cognition did not change much.6PubMed Central. Efficacy of Memantine in Schizophrenic Patients: A Systematic Review
One randomized, double-blind trial that added memantine to risperidone specifically found improvements in both negative symptoms and cognitive function at six and twelve weeks, while positive symptoms did not differ from placebo.7Psychiatry Research. Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial A follow-up study looking at chronic schizophrenia patients found that cognitive scores across nearly every domain improved after memantine was added, except for one narrow subcomponent of language (writing).8PubMed Central. Memantine as an Adjuvant in Cognitive Symptoms of Schizophrenia with a Chronic Course: A Follow-up Study
The critical detail here: in every one of these studies, memantine was used as an add-on to an existing antipsychotic, never as a replacement. Nobody is proposing that memantine can do what an antipsychotic does. It cannot control hallucinations or delusions on its own. Its potential role in schizophrenia is as a supplementary treatment aimed at the symptoms that antipsychotics leave behind.
Behavioral Symptoms in Alzheimer’s Disease
Here is where the lines blur the most. People with moderate-to-severe Alzheimer’s frequently develop agitation, aggression, and psychotic symptoms like delusions and hallucinations. Antipsychotics are often prescribed to manage these behaviors, despite carrying serious safety warnings in elderly dementia patients. Memantine, already being prescribed for the underlying cognitive decline, has shown a separate benefit on some of these behavioral symptoms.
A pooled analysis of three large studies found that memantine-treated patients were more likely to improve on a cluster of neuropsychiatric symptoms than those on placebo. For agitation and aggression specifically, about 61% of memantine patients improved by 24 to 28 weeks, compared to 45% on placebo.9PubMed. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies A meta-analysis looking at individual behavioral domains found statistically significant improvements in agitation/aggression, delusions, disinhibition, and nighttime disturbances. Hallucinations and irritability showed trends toward improvement but fell short of statistical significance.10PubMed Central. The effects of memantine on behavioral disturbances in patients with Alzheimer’s disease: a meta-analysis
These findings are clinically meaningful because they suggest memantine can partially address behavioral symptoms in dementia without requiring an antipsychotic, which carries well-documented risks for elderly patients including stroke and increased mortality. But the effect sizes are modest, and memantine is not going to eliminate severe agitation or psychosis the way a potent antipsychotic might. It is better understood as an agent that takes the edge off, potentially reducing the need for or dose of an antipsychotic rather than replacing one outright.
Quality of Life and Functional Outcomes in Schizophrenia
Beyond symptom scores, one trial measured something arguably more meaningful: whether patients actually functioned better in their daily lives. In a randomized, double-blind trial, patients receiving memantine alongside their antipsychotic showed significant improvements on both a global functioning scale and a quality-of-life measure compared to those receiving placebo plus their antipsychotic.11PubMed Central. The effect of add-on memantine on global function and quality of life in schizophrenia: A randomized, double-blind, controlled, clinical trial For a patient population that often struggles with motivation and social engagement despite adequate control of hallucinations and delusions, those kinds of improvements can matter enormously.
This is one reason the interest in memantine for schizophrenia has persisted despite the drug having no formal psychiatric indication. Negative symptoms and cognitive deficits are the primary drivers of long-term disability in schizophrenia, and the current medication toolkit does a mediocre job addressing them. A safe, well-tolerated add-on that nudges those domains in the right direction is attractive even if the effect is not transformative.
The Dopamine Angle
There is one pharmacological wrinkle that complicates the clean narrative of “memantine acts on glutamate, antipsychotics act on dopamine.” Laboratory research has found that memantine also interacts directly with dopamine D2 receptors. Specifically, it acts as an agonist at the high-affinity state of D2 receptors, with a binding potency that is in the same general range as its potency at NMDA receptors.12PubMed. Memantine agonist action at dopamine D2High receptors
This is pharmacologically interesting because antipsychotics are D2 antagonists: they block the receptor. Memantine appears to activate it, at least at its high-affinity state. That is essentially the opposite action at the same receptor. Research on striatal brain tissue has shown that memantine can shift synaptic plasticity toward a particular pattern called long-term depression in spiny projection neurons, and this effect seems to be mediated by its D2 activation.13Neuropharmacology. Memantine alters striatal plasticity inducing a shift of synaptic responses toward long-term depression
What this means in practice is still debated. The D2 interaction could contribute to some of memantine’s effects on behavior and mood, and it could theoretically either complement or partially counteract certain antipsychotic effects depending on the context. But the clinical trial data showing benefit when memantine is added to antipsychotics suggests that, at minimum, the two drugs are not working against each other in any harmful way at the doses used.
Memantine in Autism Spectrum Disorder
Autism represents another area where memantine has been tested off-label, and the rationale is slightly different. Some individuals with autism spectrum disorder have abnormally elevated glutamate levels in certain brain regions, and the thought is that an NMDA blocker might help normalize that excitatory signaling. A recent randomized trial found that among youth with autism who had elevated glutamate in a specific frontal brain region, 80% responded to memantine compared to 20% on placebo. That is a striking difference, though the subgroup was small.14JAMA Network Open. Memantine to Treat Social Impairment in Youths With Autism Spectrum Disorder: A Randomized Clinical Trial
An earlier trial in children with autism tested memantine as an add-on to risperidone (the same antipsychotic frequently used in autism for irritability and behavioral problems) and found significant reductions in irritability, stereotypic behavior, and hyperactivity compared to risperidone plus placebo.15International Journal of Neuropsychopharmacology. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial The pattern is consistent with what has been seen in schizophrenia trials: memantine seems to add something that the antipsychotic alone does not cover, rather than replicating the antipsychotic’s effects.
The glutamate biomarker finding from the JAMA Network Open study is particularly interesting because it hints at a future where memantine could be targeted to the specific individuals most likely to benefit, rather than prescribed broadly and hoping for the best. If elevated brain glutamate predicts response, a brain scan or related biomarker could guide prescribing decisions. That kind of precision is still rare in psychiatry.
Memantine and Bipolar Mania
A smaller but intriguing line of research has tested memantine in the acute manic phase of bipolar disorder. In a double-blind trial of elderly bipolar patients, those who received memantine alongside standard treatment had a greater reduction in mania severity at four and eight weeks compared to those on standard treatment alone.16PubMed Central. Evaluation of the Effect of Memantine Supplementation in the Treatment of Acute Phase of Mania in Bipolar Disorder of Elderly Patients: A Double-blind Randomized Controlled Trial This is a single study in a specific population (elderly patients), so it does not establish memantine as a mood stabilizer or anti-manic agent. But it does add to the broader picture of memantine having modulatory effects on psychiatric symptoms beyond its original cognitive-decline indication.
The common thread across all of these conditions, from Alzheimer’s behavioral disturbances to schizophrenia’s negative symptoms to mania, is glutamatergic dysfunction. Excessive or poorly regulated glutamate signaling has been implicated in all of them, and memantine’s mechanism of filtering out tonic glutamate noise while preserving phasic signaling could plausibly help in each case, even though the clinical contexts differ enormously.
Why the Antipsychotic Confusion Persists
Several factors keep the “is it an antipsychotic?” question alive. First, memantine reduces some of the same symptoms that antipsychotics are prescribed for: agitation, aggression, irritability, and certain psychotic symptoms in dementia. A patient or family member who sees these improvements might reasonably assume the drug works the same way as an antipsychotic. Second, in schizophrenia research, memantine is always studied alongside antipsychotics, which creates a natural association. Third, the D2 receptor activity described earlier adds a layer of pharmacological overlap that even some clinicians find confusing.
But the distinctions matter practically. Antipsychotics carry a specific side effect profile that includes weight gain, metabolic syndrome, movement disorders, sedation, and in elderly dementia patients, an elevated risk of death. Memantine’s side effect profile is substantially milder, dominated by dizziness, headache, and constipation. If a clinician prescribes memantine for behavioral symptoms in an Alzheimer’s patient, the risk calculation is very different from prescribing an antipsychotic. Lumping the two together as “the same kind of drug” could lead a patient to refuse memantine out of antipsychotic-related fears, or conversely, to expect antipsychotic-level symptom control from memantine and be disappointed.
Memantine and Auditory Processing
One lesser-known area of research involves memantine’s effects on a brain signal called the mismatch negativity, or MMN, which reflects how the brain automatically detects changes in sound patterns. MMN deficits are one of the most consistent neurophysiological findings in schizophrenia and are thought to reflect NMDA receptor dysfunction. In healthy volunteers, memantine increased the MMN amplitude for frequency changes, suggesting it enhanced the frontal brain generators involved in auditory change detection.17Oxford Academic (International Journal of Neuropsychopharmacology). Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review This is a niche finding, but it matters because it provides a neurophysiological signature for what memantine’s NMDA blockade is doing in the brain, offering a potential biomarker for tracking drug effects in future clinical trials.
It also underscores how different memantine is from antipsychotics. Antipsychotics do not typically improve MMN. They address downstream symptoms through dopamine blockade without fixing the underlying NMDA-related processing deficits that contribute to cognitive and perceptual problems. Memantine appears to act more upstream, at a level that antipsychotics do not reach, which is precisely why the two classes of drugs can complement each other rather than serving as substitutes.
How Memantine Is Actually Used Alongside Antipsychotics
In clinical practice, the typical scenario for combined use involves a patient with schizophrenia whose positive symptoms (hallucinations, paranoia) are well controlled on an antipsychotic but who remains apathetic, socially withdrawn, and cognitively sluggish. These residual symptoms are the primary drivers of disability and reduced quality of life, and they often persist no matter how many antipsychotic switches or dose adjustments are tried. Adding memantine at standard Alzheimer’s doses (around 20 mg per day) is one option clinicians have explored, and the evidence, while not overwhelming, points in a favorable direction.18PubMed Central. Is Memantine Effective as an NMDA-Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
It is worth noting that the trial sizes in schizophrenia research on memantine are still modest, and the high heterogeneity across studies means that results vary quite a bit from trial to trial. The meta-analytic finding on negative symptoms, while statistically robust, comes with caveats about inconsistency. Whether memantine will ever gain a formal psychiatric indication remains uncertain. For now, it sits in that gray zone of off-label treatments that clinicians can draw on when approved options fall short, guided by a reasonable but not definitive evidence base.
A parallel situation exists in autism care. When risperidone or aripiprazole (the two antipsychotics with FDA approval for irritability in autism) leave residual behavioral problems, memantine has been studied as a second agent to address what the antipsychotic alone cannot. The early trial data suggest this combination outperforms the antipsychotic plus placebo, but larger, longer studies are still needed to know how durable and generalizable the benefit is.